Targeting myeloid MIF/CD74 axis in metastatic melanoma – mechanisms, prognostication and therapeutic opportunities

Description of the granted funding

Melanoma is the 5th most prevalent form of cancer in Finland, where the inhabitants are predominantly light-skinned. In the advanced stages, melanoma cells spread from the primary site (mostly the skin) via the bloodstream to distant organs. On that stage, surgery, radiotherapy and chemotherapy are less effective. One approach to treat metastatic melanoma is immunotherapy, which boosts the body's natural defences to eliminate the cancer cells. However, several melanoma patients develop mechanisms of resistance to this therapy. We discovered that melanoma cells may produce a factor called MIF, which turn off the body's natural defences, impairing the effectiveness of immunotherapy. In this project, we will validate MIF as a tool to select those patients that are eligible to respond to immunotherapy. For those that are not eligible, we will develop adjuvant strategies that neutralize MIF to restore the body's ability to kill cancer cells, unleashing the full power of immunotherapy.
Show more

Starting year

2020

End year

2026

Granted funding

Carlos Rogerio Figueiredo Orcid -palvelun logo
438 874 €

Rogerio De Figueiredo Orcid -palvelun logo
438 874 €

Related funding decisions

358209
Research costs of Academy Research Fellows(2023)
199 402 €
336530
Research costs of Academy Research Fellows(2020)
300 022 €

Role in consortium of the Academy of Finland

Leader

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

330876

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer